The Global Viral Vector Manufacturing Market is projected to reach $1.71 billion by 2028, from a value of $0.59 billion in 2022, by registering a CAGR of 19.2% during the forecast period. Effectiveness of viral vectors, availability of funding for the development of gene therapy, and ongoing research into viral vector-based gene & cell therapies are the major factors propelling the growth of the market. However, short shelf-life of viral vectors and high costs associated with gene therapy are hampering market growth. Moreover, rising prevalence of genetic disorders, potential applications in novel drug delivery approaches, and untapped potential in emerging markets are creating ample opportunities across the globe.
Recent Developments
In June 2022, Lonza and Adva Biotechnology Ltd. (Adva) have entered into a license agreement that will provide Adva access to core intellectual property enabling the expansion of automated bioreactors globally. Through the agreement, Lonza grants Adva a non-exclusive license to certain patents in its portfolio directed to smart automation and bioreactor control. Lonza and Adva have dismissed their ongoing litigation in the United States.
In October 2021, LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies announced a strategic collaboration to support the development and manufacturing of LEXEOs adeno-associated virus (AAV)-mediated gene therapies.
In January 2021, Thermo Fisher Scientific announced around USD 880 million acquisition of Belgium-based Henogen SA, Novaseps viral victor manufacturing business. Thermo Fisher is striving to foster its capabilities for cell and gene vaccines and therapies.
In April 2020, Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility. The projected expansion was expected to double the companys gene therapy manufacturing capacity.
Competitive Landscape
Brammer Bio, Cobra Biologics, Finvector Vision Therapies, Fujifilm Holdings Corporation, Kaneka Eurogentec, Lonza, Massbiologics, Merck KGaA, Novasep, Oxford Biomedica, Regenxbio, Shape Therapeutics, Spark Therapeutics, Thermo Fisher Scientific Inc, and Uniqure are some of the major players in the global Viral Vector Manufacturing market.
